DGAP-News

MOLOGEN presented poster at ESMO WCGI 2015

DGAP-News: MOLOGEN AG / Key word(s): Conference
MOLOGEN presented poster at ESMO WCGI 2015

06.07.2015 / 13:08

---------------------------------------------------------------------

MOLOGEN presented poster at ESMO WCGI 2015

Berlin, July 6, 2015 - The biotechnology company MOLOGEN AG presented a
poster on the clinical trial IMPALA with the cancer immunotherapy MGN1703
at the ESMO 17th World Congress on Gastrointestinal Cancer (WCGI) in
Barcelona (July 1-4, 2015). The poster was titled "Immunomodulatory switch
maintenance therapy to improve overall survival in metastatic colorectal
carcinoma: The phase 3 IMPALA study" and featured information on the
rationale and design of the ongoing trial.

All abstracts from the ESMO 17th World Congress on Gastrointestinal Cancer
are published in a supplement to the Annals of Oncology journal.

For more information on the ESMO World Congress on Gastrointestinal Cancer
please visit ESMO's website www.esmo.org.

About IMPALA
IMPALA is a randomized, international, multicenter, open-label phase III
trial. The study aims to prove that a switch maintenance therapy with an
active immunotherapy leads to an increased overall survival of patients who
have achieved a response during their first line treatment of metastatic
colorectal cancer. The primary endpoint is overall survival and secondary
study endpoints include progression-free survival, toxicity and safety, and
Quality of Life (QoL). Approximately 540 patients from more than 100
European centers, including the five major pharma markets, will participate
in the study. IMPALA started to treat the first patients in mid-September.

Leading medical associations will participate: Arbeitsgemeinschaft
Internistische Onkologie (AIO) in Germany, Grupo Españiol de Tratamiento de
Tumores Digestivos (TTD) in Spain and Groupe Coopérateur Multidisciplinaire
en Oncologie (GERCOR) in France. The steering committee consists of
international medical experts; among others the coordinating study
investigators Prof. David Cunningham, MD, Department of Medicine and
Director of Clinical Research, Royal Marsden Hospital in London, and Prof.
Dirk Arnold, MD, Director of the Clinic for Medical Oncology, Klinik für
Tumorbiologie, Freiburg, Germany.

For more information on the trial IMPALA please visit
www.clinicaltrials.gov.

About MGN1703
MGN1703 is an innovative DNA-based TLR9 agonist developed by MOLOGEN that